Skip to main content
Erschienen in: Diabetologia 5/2006

01.05.2006 | Article

Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes

verfasst von: A.-M. Aas, I. Seljeflot, P. A. Torjesen, L. M. Diep, P. M. Thorsby, K. I. Birkeland

Erschienen in: Diabetologia | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Adipokines may be important in mediating signals from adipocytes to insulin-sensitive tissue and vasculature. We studied the effect of different glucose-lowering therapies on serum levels of plasminogen activator inhibitor-1 (PAI-1), high-sensitivity C-reactive protein (hs-CRP), TNF-α, leptin, adiponectin and ghrelin in patients with type 2 diabetes.

Subjects and methods

Twenty-eight patients with poorly controlled type 2 diabetes who were receiving oral hypoglycaemic agents were allocated to one of the following groups, and treated for 1 year: (1) lifestyle intervention (L); (2) insulin treatment (I); and (3) combined treatment (L+I).

Results

Similar improvements in glycaemic control occurred in all three groups. There was a reduction in body weight of 3.0 kg (median) (95% CI −5.9 to −2.0) in group L, whereas in groups L+I and I body weight increased by 3.5 kg (95% CI 1.5–4.9) and 4.9 kg (95% CI −3.1 to 8.2), respectively. By trend analyses, group L had reduced levels of PAI-1 (p=0.002), hs-CRP (p<0.0001) and TNF-α (p=0.006), while no significant changes were observed in the levels of leptin or adiponectin. In group I, the median levels of PAI-1 (p=0.008), TNF-α (p=0.058) and leptin (p=0.004) increased. In the L+I group there was a reduction in PAI-1 levels (p=0.014) and an increase in levels of leptin (p<0.001). The differences in changes in the levels of PAI-1, hs-CRP, TNF-α and leptin between groups were also significant (all p<0.01).

Conclusions/interpretation

Improvement of glycaemic control through lifestyle intervention in type 2 diabetes had more beneficial effects on adipokine levels than when the same lowering of HbA1c was achieved with insulin treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S (2005) Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288:2031–2041 Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S (2005) Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288:2031–2041
2.
Zurück zum Zitat Tataranni PA, Ortega E (2005) A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 54:917–927PubMed Tataranni PA, Ortega E (2005) A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 54:917–927PubMed
3.
Zurück zum Zitat Kereiakes DJ, Willerson JT (2003) Metabolic syndrome epidemic. Circulation 108:1552–1553PubMed Kereiakes DJ, Willerson JT (2003) Metabolic syndrome epidemic. Circulation 108:1552–1553PubMed
4.
Zurück zum Zitat Juhan-Vague I, Alessi MC, Mavri A, Morange PE (2003) Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575–1579PubMed Juhan-Vague I, Alessi MC, Mavri A, Morange PE (2003) Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575–1579PubMed
5.
Zurück zum Zitat Williams MJA, Williams SM, Milne BJ, Hancox RJ, Poulton R (2004) Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes Relat Metab Disord 28:998–1003PubMed Williams MJA, Williams SM, Milne BJ, Hancox RJ, Poulton R (2004) Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Int J Obes Relat Metab Disord 28:998–1003PubMed
6.
Zurück zum Zitat Haffner SM (2003) Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92:18–26 Haffner SM (2003) Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92:18–26
7.
Zurück zum Zitat Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMed Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978PubMed
8.
Zurück zum Zitat Maachi M, Pieroni L, Bruckert E et al (2004) Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 28:993–997PubMed Maachi M, Pieroni L, Bruckert E et al (2004) Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 28:993–997PubMed
9.
Zurück zum Zitat Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMed Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMed
10.
Zurück zum Zitat Hanley AJ, Festa A, D’Agostino RB Jr et al (2004) Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53:1773–1781PubMed Hanley AJ, Festa A, D’Agostino RB Jr et al (2004) Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53:1773–1781PubMed
11.
Zurück zum Zitat Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: The Atherosclerosis Risk in Communities Study. Diabetes 52:1799–1805PubMed Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: The Atherosclerosis Risk in Communities Study. Diabetes 52:1799–1805PubMed
12.
Zurück zum Zitat Laaksonen DE, Niskanen L, Nyyssonen K et al (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47:1402–1410 Laaksonen DE, Niskanen L, Nyyssonen K et al (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47:1402–1410
13.
Zurück zum Zitat Pai JK, Pischon T, Ma J et al (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351:2599–2610PubMed Pai JK, Pischon T, Ma J et al (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351:2599–2610PubMed
14.
Zurück zum Zitat Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMed Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMed
15.
Zurück zum Zitat Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK (2004) Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 44:1819–1824PubMed Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK (2004) Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 44:1819–1824PubMed
16.
Zurück zum Zitat Yudkin JS, Juhan-Vague I, Hawe E et al (2004) Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 53:852–857PubMed Yudkin JS, Juhan-Vague I, Hawe E et al (2004) Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 53:852–857PubMed
17.
Zurück zum Zitat Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S (1994) A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. J Intern Med 236:305–313PubMed Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S (1994) A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. J Intern Med 236:305–313PubMed
18.
Zurück zum Zitat Yki-Jarvinen H, Ryysy L, Kauppila M et al (1997) Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:4037–4043PubMed Yki-Jarvinen H, Ryysy L, Kauppila M et al (1997) Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:4037–4043PubMed
19.
Zurück zum Zitat Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130:389–396PubMed Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130:389–396PubMed
20.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853 UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
21.
Zurück zum Zitat Agurs-Collins TD, Kumanyika SK, Ten Have TR, Adams-Campbell LL (1997) A randomized controlled trial of weight reduction and exercise for diabetes management in older African–American subjects. Diabetes Care 20:1503–1511PubMed Agurs-Collins TD, Kumanyika SK, Ten Have TR, Adams-Campbell LL (1997) A randomized controlled trial of weight reduction and exercise for diabetes management in older African–American subjects. Diabetes Care 20:1503–1511PubMed
22.
Zurück zum Zitat Anderson JW, Brinkman-Kaplan V, Hamilton CC, Logan JE, Collins RW, Gustafson NJ (1994) Food-containing hypocaloric diets are as effective as liquid-supplement diets for obese individuals with NIDDM. Diabetes Care 17:602–604PubMed Anderson JW, Brinkman-Kaplan V, Hamilton CC, Logan JE, Collins RW, Gustafson NJ (1994) Food-containing hypocaloric diets are as effective as liquid-supplement diets for obese individuals with NIDDM. Diabetes Care 17:602–604PubMed
23.
Zurück zum Zitat Brown SA, Upchurch S, Anding R, Winter M, Ramirez G (1996) Promoting weight loss in type II diabetes. Diabetes Care 19:613–624PubMed Brown SA, Upchurch S, Anding R, Winter M, Ramirez G (1996) Promoting weight loss in type II diabetes. Diabetes Care 19:613–624PubMed
24.
Zurück zum Zitat Calle-Pascual AL, Rodriguez C, Camacho F et al (1992) Behaviour modification in obese subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract 15:157–162PubMed Calle-Pascual AL, Rodriguez C, Camacho F et al (1992) Behaviour modification in obese subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract 15:157–162PubMed
25.
Zurück zum Zitat Low CC, Grossman EB, Gumbiner B (1996) Potentiation of effects of weight loss by monounsaturated fatty acids in obese NIDDM patients. Diabetes 45:569–575PubMed Low CC, Grossman EB, Gumbiner B (1996) Potentiation of effects of weight loss by monounsaturated fatty acids in obese NIDDM patients. Diabetes 45:569–575PubMed
26.
Zurück zum Zitat Pascale RW, Wing RR, Blair EH, Harvey JR, Guare JC (1992) The effect of weight loss on change in waist-to-hip ratio in patients with type II diabetes. Int J Obes Relat Metab Disord 16:59–65PubMed Pascale RW, Wing RR, Blair EH, Harvey JR, Guare JC (1992) The effect of weight loss on change in waist-to-hip ratio in patients with type II diabetes. Int J Obes Relat Metab Disord 16:59–65PubMed
27.
Zurück zum Zitat Pascale RW, Wing RR, Butler BA, Mullen M, Bononi P (1995) Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. Diabetes Care 18:1241–1248PubMed Pascale RW, Wing RR, Butler BA, Mullen M, Bononi P (1995) Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. Diabetes Care 18:1241–1248PubMed
28.
Zurück zum Zitat Uusitupa M, Laitinen J, Siitonen O, Vanninen E, Pyorala K (1993) The maintenance of improved metabolic control after intensified diet therapy in recent type 2 diabetes. Diabetes Res Clin Pract 19:227–238PubMed Uusitupa M, Laitinen J, Siitonen O, Vanninen E, Pyorala K (1993) The maintenance of improved metabolic control after intensified diet therapy in recent type 2 diabetes. Diabetes Res Clin Pract 19:227–238PubMed
29.
Zurück zum Zitat Wing RR, Blair E, Marcus M, Epstein LH, Harvey J (1994) Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 97:354–362PubMed Wing RR, Blair E, Marcus M, Epstein LH, Harvey J (1994) Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 97:354–362PubMed
30.
Zurück zum Zitat Wolf AM, Conaway MR, Crowther JQ et al (2004) Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care 27:1570–1576PubMed Wolf AM, Conaway MR, Crowther JQ et al (2004) Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care 27:1570–1576PubMed
31.
Zurück zum Zitat Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI (2005) An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study. Diabet Med 22:316–322PubMed Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI (2005) An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study. Diabet Med 22:316–322PubMed
32.
Zurück zum Zitat King DE, Mainous AG III, Buchanan TA, Pearson WS (2003) C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 26:1535–1539PubMed King DE, Mainous AG III, Buchanan TA, Pearson WS (2003) C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 26:1535–1539PubMed
33.
Zurück zum Zitat Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813–823PubMed Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27:813–823PubMed
34.
Zurück zum Zitat Gustavsson CG, Agardh CD (2004) Markers of inflammation in patients with coronary artery disease are also associated with glycosylated haemoglobin A1c within the normal range. Eur Heart J 25:2120–2124PubMed Gustavsson CG, Agardh CD (2004) Markers of inflammation in patients with coronary artery disease are also associated with glycosylated haemoglobin A1c within the normal range. Eur Heart J 25:2120–2124PubMed
35.
Zurück zum Zitat Yudkin JS, Panahloo A, Stehouwer C et al (2000) The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 43:1099–1106PubMed Yudkin JS, Panahloo A, Stehouwer C et al (2000) The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 43:1099–1106PubMed
36.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMed
37.
Zurück zum Zitat Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G (1997) UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab 82:654–657PubMed Widjaja A, Stratton IM, Horn R, Holman RR, Turner R, Brabant G (1997) UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab 82:654–657PubMed
38.
Zurück zum Zitat Mattusch F, Dufaux B, Heine O, Mertens I, Rost R (2000) Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 21:21–24PubMed Mattusch F, Dufaux B, Heine O, Mertens I, Rost R (2000) Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 21:21–24PubMed
39.
Zurück zum Zitat Adamopoulos S, Parissis J, Kroupis C et al (2001) Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J 22:791–797PubMed Adamopoulos S, Parissis J, Kroupis C et al (2001) Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J 22:791–797PubMed
40.
Zurück zum Zitat Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP (1997) Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? Eur J Vasc Endovasc Surg 14:344–350PubMed Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP (1997) Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? Eur J Vasc Endovasc Surg 14:344–350PubMed
41.
Zurück zum Zitat Esposito K, Marfella R, Ciotola M et al (2004) Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292:1440–1446PubMed Esposito K, Marfella R, Ciotola M et al (2004) Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292:1440–1446PubMed
42.
Zurück zum Zitat Esposito K, Pontillo A, Di PC et al (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289:1799–1804PubMed Esposito K, Pontillo A, Di PC et al (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289:1799–1804PubMed
43.
Zurück zum Zitat Bobbert T, Rochlitz H, Wegewitz U et al (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712–2719PubMed Bobbert T, Rochlitz H, Wegewitz U et al (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712–2719PubMed
44.
Zurück zum Zitat Brinkworth GD, Noakes M, Keogh JB, Luscombe ND, Wittert GA, Clifton PM (2004) Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. Int J Obes Relat Metab Disord 28:661–670PubMed Brinkworth GD, Noakes M, Keogh JB, Luscombe ND, Wittert GA, Clifton PM (2004) Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. Int J Obes Relat Metab Disord 28:661–670PubMed
45.
Zurück zum Zitat Jaeger J, Kooy A, Lehert P et al (2005) Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 257:100–109 Jaeger J, Kooy A, Lehert P et al (2005) Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 257:100–109
46.
Zurück zum Zitat Bailey CJ (2005) Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 7:675–691PubMed Bailey CJ (2005) Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 7:675–691PubMed
47.
Zurück zum Zitat Lee KW, Lip GY (2003) Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 163:2368–2392PubMed Lee KW, Lip GY (2003) Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 163:2368–2392PubMed
48.
Zurück zum Zitat Kohler HP, Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792–1801PubMed Kohler HP, Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792–1801PubMed
49.
Zurück zum Zitat Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS (1993) Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 10:27–32PubMed Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS (1993) Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 10:27–32PubMed
50.
Zurück zum Zitat Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS (1998) Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism 47:637–643PubMed Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS (1998) Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism 47:637–643PubMed
51.
Zurück zum Zitat Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J (2003) Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 11:525–531CrossRefPubMed Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J (2003) Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 11:525–531CrossRefPubMed
Metadaten
Titel
Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes
verfasst von
A.-M. Aas
I. Seljeflot
P. A. Torjesen
L. M. Diep
P. M. Thorsby
K. I. Birkeland
Publikationsdatum
01.05.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 5/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0205-8

Weitere Artikel der Ausgabe 5/2006

Diabetologia 5/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.